Could Medicare payment models impact a physician's decision to prescribe cancer drug supplements? A recent study from The American Journal of Pharmacy Benefits published new findings that say they can.
Could Medicare payment models impact a physician’s decision to prescribe cancer drug supplements? A recent study from The American Journal of Pharmacy Benefits published new findings that say they can. The AJPB press release states:
A new study from The American Journal of Pharmacy Benefits finds that physicians who treat cancer patients may be influenced by the reimbursement policies of the Medicare claim processors that pay them. The findings also report that bundled payments, wherein all items and services given during an episode of care are paid for in one lump sum, had lower reimbursement amounts than those models that paid doctors separately for each service. This suggests that differences in Medicare reimbursement models can lead to variations in physician care delivery practices.
The study, conducted by West Virginia University researchers Dr. Xiaoyun Pan, and Dr. Usha Sambamoorthi, specifically analyzed non-Hodkin lymphoma (NHL) patients who received granulocyte colony-stimulating factor (G-CSF) as a supplement to their cancer treatment. G-CSF is used to accelerate a patient's recovery from neutropenia after chemotherapy.
“G-CSF is listed as one of the top 10 most expensive Medicare Part B drugs, with average reimbursement amounts for 11 days of supply ranging from $2136 to $3442,” wrote the study authors. “Thus, augmenting chemotherapy with G-CSF may provide increased revenue for the physicians.”
Research findings revealed that G-CSF prescription was less likely in locations with higher physician reimbursement models when compared to those processors with lower average physician reimbursement amounts. While the study did not specifically ask for physicians reasoning in prescribing the supplementary drug, the authors speculate that variation in G-CSF use is likely directly linked with low reimbursement amounts.
The full release can be read here.
Covering antiobesity medications like semaglutide could save Medicare around $500 million annually; preliminary CDC data showed a 3% decline in the number of US overdose deaths last year; the Biden administration recently announced the first national maternal mental health strategy.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Panel Addresses Minority Physician Shortage, Maternal Health at Senate Committee Hearing
May 15th 2024The senate hearing held by the US Senate Committee on Health, Education, Labor, and Pensions, led by Sen. Bernie Sanders (I, Vermont), chairman of the committee, and ranking member Sen. Bill Cassidy, MD, (R, Louisiana), addressed the critical issue of physician and health care worker shortages, as well as the maternal health crisis, in the US.
Read More
A new study highlights significant disparity in reimbursement rates across states between hospitals and Medicare; the first patient to receive a genetically modified pig kidney has died; research examines outcomes of over 500 patients receiving medication abortion pills by mail.
Read More